Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy

Area of Science:

• Neuro-oncology
• Immunotherapy
• Nanomedicine

Background:

• Checkpoint inhibitor antibodies (anti-CTLA-4, anti-PD-1) show promise in cancer treatment but are limited in brain glioma therapy due to the blood-brain barrier (BBB).
• Systemic delivery of these inhibitors fails to reach therapeutic concentrations within the brain tumor microenvironment.

Purpose of the Study:

• To develop targeted nanoscale immunoconjugates (NICs) for effective delivery of checkpoint inhibitors across the BBB.
• To evaluate the efficacy of NICs in activating a local anti-tumor immune response within the brain.

Main Methods:

• Development of NICs using a poly(β-L-malic acid) scaffold with covalently attached anti-CTLA-4 or anti-PD-1 antibodies.
• Treatment of mice with intracranial GL261 glioblastoma (GBM) models using NICs.
• Analysis of immune cell populations (CD8+ T cells, NK cells, macrophages, Tregs) within the brain tumor area.
• Assessment of survival rates in treated GBM-bearing mice.

Main Results:

• NICs successfully crossed the BBB, enabling targeted delivery of checkpoint inhibitors.
• NIC treatment led to an increased infiltration of CD8+ T cells, NK cells, and macrophages in the tumor site.
• A decrease in regulatory T cells (Tregs) was observed within the brain tumor microenvironment.
• Combination NIC therapy significantly enhanced survival in GBM-bearing mice compared to single-agent or unconjugated inhibitors.

Conclusions:

• Targeted polymer-conjugated checkpoint inhibitors delivered via NICs represent a viable strategy for overcoming BBB limitations in GBM treatment.
• This approach effectively activates both systemic and local brain anti-tumor immunity, leading to improved therapeutic outcomes.
• NICs hold potential for treating brain gliomas by enhancing the immune system's ability to combat tumors within the central nervous system.